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Abstract
C1q, historically viewed as the initiating component of the classical complement pathway, also 
exhibits a variety of complement-independent activities in both innate and acquired immunity. 
Recent studies focusing on C1q’s suppressive role in the immune system have provided new 
insight into how abnormal C1q expression and bioactivity may contribute to autoimmunity. In 
particular, molecular networks involving C1q interactions with cell surface receptors and other 
ligands are emerging as mechanisms involved in C1q’s modulation of immunity. Here, we discuss 
the role of C1q in controlling immune cell function, including recently elucidated mechanisms of 
action, and suggest how these processes are critical for maintaining tissue homeostasis under 
steady-state conditions and in preventing autoimmunity.
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Introduction
The first complement component, C1q, accomplishes a diverse range of complement-
dependent and complement-independent functions in the immune response [1, 2]. It binds 
various ligands derived from self and non-self and modulates the functions of immune cells. 
It is well known that abnormal regulation of immune cells and break down of homeostasis 
cause autoimmune disease, including lupus. This review stresses the tolerogenic role of C1q 
and provides mechanistic insight into how genetic deficiency of C1q leads to systemic lupus 
erythematosus (SLE).
C1q structure and ligands
C1q is a 460 kDa macromolecule found circulating in blood. It is composed of 18 
polypeptide chains (six trimers of C1qa, C1qb and C1qc). It contains an N-terminal triple-
helical collagen-like region (C1q tail) and a C-terminal globular head region (gC1q) [3, 4]. 
The gC1q has similar structure to tumor necrosis factor (TNF) and belongs to the C1q/TNF 
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superfamily which is involved in inflammation [5]. The C1q tail has the repeating sequence 
G-X–Y (X is any amino acid and Y is proline or hydroxyproline) characteristic of collagen. 
C1q also belongs to the collectin family which includes mannose-binding lectin, surfactant 
protein A (SP-A), SP-D, and ficolin which are pattern recognition proteins of the innate 
immune system [6, 7].
C1q is one of the most highly positively charged proteins in human serum; based on this and 
other chemical features, C1q (especially its globular region) has been classified as a charged 
pattern recognition molecule recognizing a wide variety of both self and non-self-ligands [8–
11]. C1q binds to molecules released from apoptotic and necrotic cells including 
phosphatidylserine, nucleic acids, and other damage-associated molecular patterns (DAMPs) 
[12, 13]. In addition, C1q can bind altered self-proteins including β-amyloid [14], prion [15, 
16], oxidized low-density lipoprotein [17], DNA and heparin sulfate [18]. In response to 
infection, C1q binds to pathogen-associated molecular patterns (PAMPs) on viruses and 
bacteria including lipopolysaccharide [19, 20].
The role of C1q in apoptotic cell clearance: C1q and C1q receptors
The diversity of ligands for C1q relates in part to its domains, the gC1q and C1q tail regions, 
which bind specific cell surface receptors to regulate both innate and adaptive immunity. 
Most receptors described for the gC1q and C1q tail domains are involved in phagocytic 
uptake by macrophages, functioning in the clearance of dead and dying cells. This well-
recognized role of C1q in innate immunity is aimed at preventing inflammation caused by 
the release of intracellular cytotoxic substances into the extracellular space [12, 21, 22]. A 
growing number of C1q receptors include gC1qR (p33 or C1qBP), CD91, CD35, α2β1, 
CD93 (C1qRp), calreticulin (CRT, cC1qR), β-integrin, dendritic cell-specific intercellular 
adhesion molecule-3-grabbing non-integrin (DC-SIGN, CD209), receptor for advanced 
glycation endproducts (RAGE) and leukocyte-associated immunoglobulin-like receptor 1 
(LAIR-1, CD305) [23–27].
CD91 (low-density lipoprotein receptor-related protein 1) is a transmembrane protein that 
associates with the co-receptor calreticulin on the surface of macrophages and microglial 
cells [28, 29] to initiate the clearance of C1q-bound apoptotic cargo [22, 30]. Calreticulin, 
initially described as a molecular chaperone in the endoplasmic reticulum (ER), was the first 
receptor identified for the C1q tail and requires a conformational change in C1q in order to 
bind the C1q tail [31]. More recently, calreticulin has been shown to interact with both gC1q 
and C1q tail domains and to function as a phosphatidylserine recognition molecule on the 
apoptotic cell surface [32]. RAGE is a member of the Ig superfamily and belongs to the class 
of type I cell surface receptors expressed on all types of leukocytes. RAGE binds gC1q and 
enhances C1q-mediated phagocytosis [33]. The scavenger receptor Scarf1 has also been 
described as a C1q-dependent receptor for apoptotic cell clearance [34]. Scarf1-deficiency 
leads to spontaneous autoimmune disease and global activation of T cells, follicular helper T 
cells and B cells suggesting a role of Scarf1/C1q interactions in preventing autoimmunity. 
C1q also elicits macrophage expression of the Mer tyrosine kinase (Mer) which results in 
enhanced clearance of apoptotic debris [35].
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New insights into tolerogenic functions of C1q
Aside from facilitating phagocytosis, C1q regulates immune cell differentiation, cytokine 
secretion and macrophage polarization toward a tolerogenic phenotype [36, 37]. Recent 
studies related to C1q-facilitated phagocytosis reveal that aside from clearance of apoptotic 
debris, C1q-mediated uptake of apoptotic lymphocytes by human macrophages and DCs 
actively promotes tolerogenic activity (Fig. 1a, [38]). In this case, C1q-exposed 
macrophages and DCs exhibit a reduced capacity to produce pro-inflammatory cytokines, 
diminished ability to promote inflammatory type T helper (Th) 1/Th17 responses as well as 
a tendency toward sustaining regulatory T cells. The ability of C1q to engage in molecular 
complexing at the cell surface is also emerging as an important regulatory function. In 
immature monocyte-derived DCs (moDCs), C1q, DC-SIGN and gC1qR form a trimolecular 
complex on the plasma membrane which is presumed to modulate DC differentiation and 
function through DC-SIGN-mediated signaling pathways [26].
LAIR-1 (CD305) is a transmembrane protein containing two immunoreceptor tyrosine 
inhibitory motifs (ITIM) and is an ubiquitous collagen receptor expressed on a variety of 
immune cells [39, 40]. Recently, we identified LAIR-1 as the first known inhibitory receptor 
for C1q [25, 41]. Binding of C1q’s collagen tail to LAIR-1 on monocytes leads to 
phosphorylation of LAIR-1 ITIMs, recruitment of SHP-1, and interruption of downstream 
signal transduction associated with the production of pro-inflammatory cytokines and 
monocyte-derived DC growth factors. We also showed that binding of C1q to LAIR-1 on 
plasmacytoid (p) DCs restricts the production of type I interferons, which are important in 
antiviral defenses and sustaining moDC differentiation [25] (Fig. 1b, c). Similar to C1q, 
surfactant protein D (SP-D) possesses an N-terminal helical collagen domain and was 
recently found to also engage LAIR-1 and restrict myeloid cell activity [42].
Thus, growing understanding of distinct interactions between C1q and cell-associated 
receptors with endogenous and exogenous stress molecules has provided insight into how 
C1q-facilitated uptake of apoptotic cells and signal transduction may help censor damaging 
inflammation and autoimmunity [38, 43]. Which molecular interactions with C1q (either 
devoid of or containing immunogenic cargo) predominate in distinct anatomical locations 
and physiological settings remains an important area of study.
Genetic and functional deficiency of C1q in SLE
Systemic lupus erythematosus (SLE) is an autoimmune disease that involves profound 
abnormalities in both the myeloid and lymphoid cell compartments. In SLE, C1q deficiency 
may result either from genetic defects or C1q-targeted autoantibodies [23, 44]. The 
observation that SLE develops in approximately 90 % of patients genetically deficient in 
C1q introduced the concept that, aside from its role in activating the complement cascade, 
C1q functions to prevent autoimmunity [45]. Studies of C1q−/− mice revealing a 
spontaneous lupus-like disease characterized by the development of antinuclear antibodies 
and glomerulonephritis associated with failure to clear apoptotic bodies provided some 
insight into a complement-independent role [46]. Moreover, associations between single 
nucleotide polymorphisms (SNPs) in C1q and specific clinical phenotypes have been 
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reported [47, 48]. Based on these observations, possible explanations of C1q deficiency 
contributing to the development of SLE are the following: (1) impaired apoptotic cell 
clearance [46] consistent with the increased presence of apoptotic cells in lymph nodes and 
tissues of SLE patients and C1q−/− mouse models [49, 50]; (2) abnormal development of 
self-reactive B cells with specificities toward multiple autoantigens [51]; (3) lack of 
tolerogenic activity on monocytes/macrophages and DCs [52, 53]; and (4) failure to control 
monocyte to DC differentiation [25, 54].
In SLE, C1q deficiency may occur as a result of autoantibodies to C1q. Anti-C1q antibodies 
were initially identified in pathogenic immune complexes in SLE patients [55, 56]. They 
have been linked to lupus nephritis, a severe manifestation of SLE, and are present in 30–
50 % of lupus patients [57, 58]. While antibodies to both gC1q and C1q collagen tail have 
been identified, the consequence of blocking C1q domains on its biological activity is not 
firmly established. In the kidney, anti-C1q antibodies may participate in lupus pathogenesis 
by contributing to the formation of immune complexes. Impairment of C1q’s role in 
promoting tolerance could also result from anti-C1q antibodies interfering with the ability of 
C1q to promote the uptake of apoptotic debris or immune complexes. Anti-C1q antibodies 
(notably to the C1q tail) might also contribute to SLE by blocking the interaction of the C1q 
tail with its inhibitory receptor, LAIR-1 on monocytes, pDCs and B cells, all of which are 
profoundly abnormal in SLE.
C1q in the central nervous system (CNS)
In the brain, C1q has been ascribed an important role in shaping neuronal architecture by 
participating in synaptic pruning, a process whereby functional neuronal synapses are 
produced during development [59, 60]. In addition, there is evidence to substantiate that C1q 
guards against neural inflammation in the brain [2]. C1q-mediated complement-dependent 
and complement-independent activities are both associated with synaptic pruning, which 
involves uptake by macrophage-like microglia cells in the brain [59, 60]. C1q−/− mice fail to 
produce normal synaptic connectivity in the neocortex, suggesting that C1q is involved in 
synaptic pruning during the development of the central nervous system (CNS) [59]. 
Moreover, sustained defects in synapse elimination in C1q knockout mice lead to 
neurodegenerative disease [61]. In the C1q−/− model of epilepsy, the failure of synaptic 
pruning induces increased dendritic length, branching and density of dendritic spines [62]. 
Based on these collective findings, C1q has a key role in shaping neuronal connectivity by 
directing the uptake of unwanted synapses into microglia for clearance.
With advanced age, C1q levels are dramatically increased (as much as 300-fold) in mouse 
and human brains, including in areas of synapses [63]. In support of the idea that 
complement-mediated synapse elimination plays a role in neurodegenerative disease, C1q 
activates the complement cascade in Alzheimer’s disease (AD) [63, 64], a disease associated 
with advanced age and massive synapse loss [65]. C1q binds amyloid-β (Aβ), a misfolded 
protein associated with AD, to activate complement-dependent destruction of neurons [66, 
67]. Complement-independent functions of C1q in AD are also suggested by interactions 
with C1q receptors. RAGE is one of the several known receptors for Aβ and C1q [33] and 
may drive inflammation associated with the progression of neurodegenerative disorders by 
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activating the pro-inflammatory Jak-STAT and NF-kB signaling pathways [68, 69]. Thus, 
C1q/Aβ and RAGE complexes may regulate neuronal inflammation. C1q has also been 
shown to improve neuronal viability and neurite outgrowth and prevent Aβ-induced 
neurotoxicity in vitro [70]. Intact C1q but not gC1q, C1q tails or heat-inactivated C1q is 
required for neuroprotection [71, 72]. Thus, while particular physiological settings in the 
brain or peripheral tissue may be associated with C1q-mediated activation of the 
complement cascade, in the absence of other complement components, C1q complement-
independent functions may operate. Given that LAIR-1 is expressed in the brain [73], it is 
tempting to speculate that LAIR-1/C1q partnering contributes to guarding against 
unwarranted inflammatory activity in this tissue.
Conclusion
C1q has long been considered an innate immune molecule. Its complement-independent 
functions on immune and non-immune cells serve to highlight a critical role in maintaining 
homeostasis. C1q’s interaction with novel receptors linked to immune tolerance and 
prevention of autoimmunity and neuronal inflammation are fascinating areas for further 
investigation.
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C1q has a fundamental suppressive role in immune homeostasis. a. In well-described 
apoptotic cell clearance pathways, C1q interacts with a variety of gC1q and C1q tail 
receptors on phagocytic cells, leading to modulation of cytokine production/inflammatory 
responses. b and c. Interaction between the C1q collagen tail and LAIR-1 prevents the 
production of type I IFNs and inflammatory cytokines by pDCs and monocytes and inhibits 
DC differentiation and activation either during steady state or inflammation. PDC 
plasmacytoid DC, Mono monocyte, moDC monocyte-derived dendritic cell
Son et al. Page 10
Immunol Res. Author manuscript; available in PMC 2016 June 06.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
